In silico design: Extended molecular dynamic simulations of a new series of dually acting inhibitors against EGFR and HER2

Loading...
Thumbnail Image

Date

2013

Journal Title

Journal ISSN

Volume Title

Type

Article

Publisher

Elsevier Inc.

Series Info

Journal of Molecular Graphics and Modelling
44

Scientific Journal Rankings

Abstract

Based on the hit structures that have been identified in our previous studies against EGFR and HER2, new potential inhibitors that share the same scaffold of the hit structures are designed and screened in silico. Insights into understanding the potential inhibitory effect of the new inhibitors against both EGFR and HER2 receptors is obtained using extended molecular dynamics (MD) simulations and different scoring techniques. The binding mechanisms and dynamics are detailed with respect to two approved inhibitors against EGFR (lapatinib) and HER2 (SYR127063). The best scoring inhibitor (T9) is chosen for additional in silico investigation against both the wild-type and T790M mutant strain of EGFR and the wild-type HER2. The results reveal that certain substitution patterns increase the stability and assure stronger binding and higher H-bond occupancy of the conserved water molecule that is commonly observed with kinase crystal structures. Furthermore, the new inhibitor (T9) forms stable interactions with the mutant strain as a direct consequence of the enhanced ability to form additional hydrogen bonding interactions with binding site residues. 2013 Elsevier Ltd. All rights reserved.

Description

Scopus

Keywords

October University for Modern Sciences and Arts, جامعة أكتوبر للعلوم الحديثة والآداب, University of Modern Sciences and Arts, MSA University, AM1-D, EGFR/HER2, Molecular dynamics, Tyrosine kinase, Water occupancy, Amino acids, Bins, Enzymes, Hydrogen bonds, Molecules, Scaffolds, Binding mechanisms, EGFR/HER2, Hydrogen bonding interactions, Molecular dynamics simulations, Potential inhibitors, Scoring techniques, Substitution patterns, Tyrosine kinase, Molecular dynamics, epidermal growth factor receptor kinase inhibitor, erlotinib, gefitinib, lapatinib, protein tyrosine kinase inhibitor, quinazoline derivative, syr 127063, unclassified drug, article, binding site, crystal structure, hydrogen bond, molecular dynamics, nonhuman, priority journal, simulation, AM1-D, EGFR/HER2, Molecular dynamics, Tyrosine kinase, Water occupancy, Binding Sites, Computer Simulation, Drug Design, Humans, Ligands, Molecular Conformation, Molecular Docking Simulation, Molecular Dynamics Simulation, Protein Binding, Protein Kinase Inhibitors, Quantitative Structure-Activity Relationship, Receptor, Epidermal Growth Factor, Receptor, erbB-2, Water

Citation

Full Text link